

Curriculum Vitae

Personal information **Maria Winqvist**

Work experience

1. Employer: Karolinska University Hospital
 - Start date: 012014
 - End date: 052020
 - Position: Resident and Consultant
 - Activities: Department of Hematology
 - Country: Sweden
2. Employer: Karolinska University Hospital
 - Start date: 062020
 - End date: 032022
 - Position: Consultant
 - Activities: Department of Emergency Medicine
 - Country: Sweden
3. Employer: Swedish Medical Product Agency
 - Start date: 042022
 - End date:
 - Position: Clinical Investigator
 - Activities:
 - Country: Sweden

Education and training

1. Subject: Karolinska Institutet
 - Start date: 052016
 - End date: 052020
 - Qualification: Ph.D.
 - Organisation:
 - Country: Sweden
2. Subject: Karolinska Institutet
 - Start date: 012005
 - End date: 062011
 - Qualification: M.D.
 - Organisation:
 - Country: Sweden

Additional information

Publications

Publications 1. Winqvist M, Askild A, Andersson P-O, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L and Österborg A. Realworld results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program. *Haematologica* 2016;101(12):1573-80. 2. Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A and Lundin J. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T Cells and immune checkpoints. *Cancer Immunol Immunother* 2017;66(1):91-102. 3. Stasilojc G, Winqvist M, Blom A and Österborg A. Monitoring of hemolytic activity of serum during alemtuzumab/ofatumumab therapy of chronic lymphocytic leukemia. *Molecular Immunology* 2017;89:203. 4. Askild A, Winqvist M, Eketorp Sylvan S, Mattsson A, Björqvinnsson E, Söltoft F, Repits J, Diels J, Österborg A and Hansson L. Outcomes of second_line treatment in chronic lymphocytic leukemia – a populationbased study from a well defined geographical region between 2003 and 2013. *Leukemia & Lymphoma* 2017;58(5):1219-23. 5. Winqvist M, Palma M, Heimersson K, Mellstedt H, Österborg A and Lundin J. Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease_negativity in the bone marrow of poor_prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections _ Results from a phase I study. *Br J Haematol*. 2018;182(4):590-4. 6. Winqvist M, Andersson P-O, Askild A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L and Österborg A. Long_term real_world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30_month follow up of the Swedish compassionate use cohort. *Haematologica*. 2019;104(5):E208-E10. 7. Askild A, Eketorp Sylvan S, Mattsson A, Winqvist M, Johansson H, Österborg A and Hansson L. A real_world study of first_line therapy in 280 consecutive Swedish patients ≥ 80 years with newly diagnosed diffuse large B_cell lymphoma: very elderly (≥ 85 years) do well on curative intended therapy. *Leukemia & Lymphoma*, 2020; 61(7):1-9. 8. Mattsson A, Eketorp Sylvan S, Askild A, Wiggh J, Winqvist M, Lundin J, Mansouri L, Rosenquist R, Johansson H, Österborg A and Hansson L. Risk_adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukemia (CLL): A regional real_world report on 141 consecutive Swedish patients. *Br. J. of Haematology*, 191:426-432.

Projects

Memberships

Other Relevant Information